Predictive Markers for the Efficacy of Anti–PD-1/PD-L1 Antibodies in Lung Cancer von Shukuya, Takehito, Carbone, David P.

Volltext

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting von Abernethy, Amy P, Arunachalam, Ashwini, Burke, Thomas, McKay, Caroline, Cao, Xiting, Sorg, Rachael, Carbone, David P

Volltext

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label,... von Paz-Ares, Luis, Ciuleanu, Tudor-Eliade, Cobo, Manuel, Schenker, Michael, Zurawski, Bogdan, Menezes, Juliana, Richardet, Eduardo, Bennouna, Jaafar, Felip, Enriqueta, Juan-Vidal, Oscar, Alexandru, Aurelia, Sakai, Hiroshi, Lingua, Alejo, Salman, Pamela, Souquet, Pierre-Jean, De Marchi, Pedro, Martin, Claudio, Pérol, Maurice, Scherpereel, Arnaud, Lu, Shun, John, Thomas, Carbone, David P, Meadows-Shropshire, Stephanie, Agrawal, Shruti, Oukessou, Abderrahim, Yan, Jinchun, Reck, Martin

Volltext

Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR... von Furuya, Naoki, He, Kai, Carbone, David P.

Volltext

Non–Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy von Carbone, David P., Gandara, David R., Antonia, Scott J., Zielinski, Christoph, Paz-Ares, Luis

Volltext

Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival von Andersen, Barbara L, Myers, John, Blevins, Tessa, Park, Kylie R, Smith, Rachel M, Reisinger, Sarah, Carbone, David P, Presley, Carolyn J, Shields, Peter G, Carson, William E

Volltext

Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY... von Morgensztern, Daniel, Besse, Benjamin, Greillier, Laurent, Santana-Davila, Rafael, Ready, Neal, Hann, Christine L, Glisson, Bonnie S, Farago, Anna F, Dowlati, Afshin, Rudin, Charles M, Le Moulec, Sylvestre, Lally, Satwant, Yalamanchili, Sreeni, Wolf, Jürgen, Govindan, Ramaswamy, Carbone, David P

Volltext

PDL1 Regulation by p53 via miR-34 von Cortez, Maria Angelica, Ivan, Cristina, Valdecanas, David, Wang, Xiaohong, Peltier, Heidi J, Ye, Yuping, Araujo, Luiz, Carbone, David P, Shilo, Konstantin, Giri, Dipak K, Kelnar, Kevin, Martin, Desiree, Komaki, Ritsuko, Gomez, Daniel R, Krishnan, Sunil, Calin, George A, Bader, Andreas G, Welsh, James W

Volltext

Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors von Memmott, Regan M., Wolfe, Adam R., Carbone, David P., Williams, Terence M.

Volltext

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers von BERGETHON, Kristin, SHAW, Alice T, MARK, Eugene J, BATTEN, Julie M, HAIQUAN CHEN, WILNER, Keith D, KWAK, Eunice L, CLARK, Jeffrey W, CARBONE, David P, HONGBIN JI, ENGELMAN, Jeffrey A, MINO-KENUDSON, Mari, IGNATIUS OU, Sai-Hong, PAO, William, IAFRATE, A. John, KATAYAMA, Ryohei, LOVLY, Christine M, MCDONALD, Nerina T, MASSION, Pierre P, SIWAK-TAPP, Christina, GONZALEZ, Adriana, RONG FANG

Volltext

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial von Chaft, Jamie E., Oezkan, Filiz, Kris, Mark G., Bunn, Paul A., Wistuba, Ignacio I., Kwiatkowski, David J., Owen, Dwight H., Tang, Yan, Johnson, Bruce E., Lee, Jay M., Lozanski, Gerard, Pietrzak, Maciej, Seweryn, Michal, Byun, Woo Yul, Schulze, Katja, Nicholas, Alan, Johnson, Ann, Grindheim, Jessica, Hilz, Stephanie, Shames, David S., Rivard, Chris, Toloza, Eric, Haura, Eric B., McNamee, Ciaran J., Patterson, G. Alexander, Waqar, Saiama N., Rusch, Valerie W., Carbone, David P.

Volltext

SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer von Bell, Erica Hlavin, Chakraborty, Arup R, Mo, Xiaokui, Liu, Ziyan, Shilo, Konstantin, Kirste, Simon, Stegmaier, Petra, McNulty, Maureen, Karachaliou, Niki, Rosell, Rafael, Bepler, Gerold, Carbone, David P, Chakravarti, Arnab

Volltext

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer von Gettinger, Scott N, Horn, Leora, Gandhi, Leena, Spigel, David R, Antonia, Scott J, Rizvi, Naiyer A, Powderly, John D, Heist, Rebecca S, Carvajal, Richard D, Jackman, David M, Sequist, Lecia V, Smith, David C, Leming, Philip, Carbone, David P, Pinder-Schenck, Mary C, Topalian, Suzanne L, Hodi, F Stephen, Sosman, Jeffrey A, Sznol, Mario, McDermott, David F, Pardoll, Drew M, Sankar, Vindira, Ahlers, Christoph M, Salvati, Mark, Wigginton, Jon M, Hellmann, Matthew D, Kollia, Georgia D, Gupta, Ashok K, Brahmer, Julie R

Volltext

Circulating MicroRNAs and Extracellular Vesicle–Containing MicroRNAs as Response Biomarkers of Anti–programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Therapy in NSCLC... von Shukuya, Takehito, Ghai, Vikas, Amann, Joseph M., Okimoto, Tamio, Shilo, Konstantin, Kim, Taek-Kyun, Wang, Kai, Carbone, David P.

Volltext

Development of new techniques and clinical applications of liquid biopsy in lung cancer management von Chen, Kezhong, He, Yue, Wang, Wenxiang, Yuan, Xiaoqiu, Carbone, David P., Yang, Fan

Volltext

Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC von Rolfo, Christian, Mack, Philip C., Scagliotti, Giorgio V., Baas, Paul, Barlesi, Fabrice, Bivona, Trever G., Herbst, Roy S., Mok, Tony S., Peled, Nir, Pirker, Robert, Raez, Luis E., Reck, Martin, Riess, Jonathan W., Sequist, Lecia V., Shepherd, Frances A., Sholl, Lynette M., Tan, Daniel S.W., Wakelee, Heather A., Wistuba, Ignacio I., Wynes, Murry W., Carbone, David P., Hirsch, Fred R., Gandara, David R.

Volltext

Response to the Letter to the Editor Titled “First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA” von Paz-Ares, Luis G., Carbone, David P.

Volltext

Small cell lung cancer: Subtypes and therapeutic implications von Wang, Walter Z., Shulman, Alyssa, Amann, Joseph M., Carbone, David P., Tsichlis, Philip N.

Volltext

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512)... von Neal, Joel W, Dr, Dahlberg, Suzanne E, PhD, Wakelee, Heather A, MD, Aisner, Seena C, Prof, Bowden, Michaela, PhD, Huang, Ying, MD, Carbone, David P, Prof, Gerstner, Gregory J, MD, Lerner, Rachel E, MD, Rubin, Jerome L, MD, Owonikoko, Taofeek K, MD, Stella, Philip J, MD, Steen, Preston D, MD, Khalid, Ahmed Ali, MD, Ramalingam, Suresh S, Prof

Volltext

Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion sc... von She, Longjiang, Hu, Huabin, Liao, Mengting, Xia, Xuefeng, Shi, Yin, Yao, Linli, Ding, Dong, Zhu, Youwen, Zeng, Shan, Shen, Liangfang, Huang, Jin, Carbone, David P.

Volltext